CD63+ CAFs may promote tamoxifen resistance by secreting exosomes rich in miR-22, which can induce downregulation of ER and PTEN, to confer tamoxifen resistance on breast cancer cells (Figure 2B) (60). This evidence concerns the gene ESR1 and breast carcinoma.